Concerns around tech companies overspending on artificial intelligence grew, and traders digested U.S. data that pointed to persistent inflation.
The read-through is clearest for Moderna, which is already developing a personalized mRNA cancer vaccine with Merck. The stock is up more than 600% so far in 2026, the best performing S&P 500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results